EntryPoint Capital LLC Purchases New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

EntryPoint Capital LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 463 shares of the biopharmaceutical company’s stock, valued at approximately $330,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in REGN. Willner & Heller LLC grew its stake in Regeneron Pharmaceuticals by 3.9% during the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock worth $284,000 after buying an additional 15 shares during the last quarter. OLD Second National Bank of Aurora raised its position in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock valued at $2,025,000 after purchasing an additional 15 shares during the last quarter. Rakuten Securities Inc. grew its position in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 15 shares during the last quarter. TD Private Client Wealth LLC raised its holdings in shares of Regeneron Pharmaceuticals by 9.6% in the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 15 shares during the last quarter. Finally, Manchester Capital Management LLC raised its stake in Regeneron Pharmaceuticals by 12.6% during the 4th quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company’s stock valued at $115,000 after acquiring an additional 18 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Truist Financial reduced their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Canaccord Genuity Group cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. Citigroup decreased their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. BMO Capital Markets dropped their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a report on Tuesday, February 4th. Finally, Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Down 0.7 %

REGN stock opened at $635.83 on Friday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a 50 day simple moving average of $684.76 and a 200-day simple moving average of $803.87. The company has a market capitalization of $69.51 billion, a P/E ratio of 16.61, a PEG ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a twelve month low of $629.02 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the company earned $11.86 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% on a year-over-year basis. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.55%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.